Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

by lowes1 on September 27, 2013

Conditions:   Non Small Cell Lung Cancer;   Lung Cancer
Intervention:   Drug: defactinib (VS-6063)
Sponsors:   Verastem, Inc.;   Verastem, Inc.
Recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: